New drug combination for advanced kidney cancer

Scientists have identified a promising new drug for renal cell carcinoma (RCC); X4P-001 is an oral drug that blocks the cytokine receptor CXCR4. In an ongoing phase 1/2 trial, X4P-001 has been given to patients with advanced RCC in combination with the tyrosine kinase inhibitor axitinib. Preliminary results from the phase 1 part of the […]

read more

Targeted therapies with immunotherapies in kidney cancer

The following video is an interview with Professor Thomas Powles from Barts Cancer Centre in London, where he is Professor of Genitourinary Oncology. During the interview, Professor Powles discusses the results of the phase III KEYNOTE-426 trial presented at the 2019 Genitourinary Cancers Symposium.  The data from KETNOTE-426 potentially redefines the standard of care in […]

read more

Pembrolizumab plus axitinib granted FDA approval for advanced kidney cancer

The Food and Drug Administration (FDA) in the United States has approved the pembrolizumab (Keytruda) plus axitinib (Inlyta) combination for first-line treatment of advanced renal cell carcinoma (RCC). The approval comes two months earlier than expected and is based on the results from the open-label KEYNOTE-426 study involving 861 patients. In this study, median progression-free […]

read more

Dalantercept plus axitinib combination for advanced kidney cancer

The results from a recent phase II study comparing a combination of dalantercept plus axitinib with axitinib plus placebo for second-line treatment of advanced renal cell carcinoma (RCC) were published in the journal Cancer this month. The study involved 124 patients with clear cell RCC who had been previously treated with an angiogenesis inhibitor, such […]

read more

ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Toni Choueiri from the Dana-Farber Cancer Institute and Harvard Medical School in Boston, USA, presented updated results from the JAVELIN Renal 101 clinical trial. The results showed that treatment with a […]

read more

ASCO GU 2019: Pembrolizumab plus axitinib versus sunitinib for untreated metastatic RCC

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Professor Thomas Powles from the Barts Cancer Institute in London presented the results from KEYNOTE-426, a global, open-label, phase 3 study to assess the efficacy and safety of pembrolizumab plus […]

read more

ASCO GU 2019: Gemcitabine plus axitinib in patients with sarcomatoid renal cell carcinoma (RCC)

Results from this trial for sarcomatoid renal cell carcinoma (RCC) patients were reported at the American Society of Clinical Oncology (ASCO) genitourinary (GU) conference held in San Francisco in February 2019. Because there are limited treatment options for this aggressive form of RCC, the trial was designed to verify anecdotal reports of good responders to […]

read more

Second-line treatment with axitinib in favourable risk patients

Results from a phase 2 study to assess the activity of axitinib in patients with metastatic renal cell carcinoma (RCC) with a favourable risk (FavorAx) after having received first-line treatment with a vascular endothelial growth factor receptor (VEGFR)-directed therapy. In this study, median progression-free survival was 19 months, and the study achieved its primary endpoint based on […]

read more

Comparison of axitinib and sunitinib as first-line treatment for metastatic kidney cancer

This multicentre analysis of axitinib versus sunitinib used as first-line treatment for metastatic renal cell carcinoma (RCC) in 169 patients shows that compared with sunitinib, axitinib significantly prolonged cancer-specific survival and overall survival. Axitinib also had a safer adverse event profile compared to sunitinib as a first-line therapy for previously untreated metastatic RCC. Read the […]

read more

Results from JAVELIN Renal 101 clinical trial – avelumab plus axitinib combination for advanced kidney cancer

The following article from Practice Update discusses the JAVELIN Renal 101 clinical trial, which compares avelumab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma (RCC). The article highlights the results of this particular trial and touches upon other combinations of vascular endothelial growth factor (VEGF) inhibitors with immunotherapy as having not just […]

read more
Showing 31 to 40 of 65 results
  TOP